ApprovalTrail

Approval · Notice of Compliance 36081 · 2025

TEVA-FINASTERIDE: Notice of Compliance 36081

Issued September 29, 2025

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
36081
Date
September 29, 2025
Company
Teva Canada LimitedToronto, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to an Abbreviated New Drug Submission (SANDS), supplement
Submission class
Other
Reason
Update to Product Monograph (to align with CRP approved PM) . Update to package insert
Canadian reference product
PROSCAR (Merck Frosst Canada Inc.)

Products in this notice

BrandDINStatus today
TEVA-FINASTERIDENot yet assigned—

Medicinal ingredients